Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

Leukemia

Volumn 22, Issue 2, 2008, Pages 414-423

  Palumbo, A ^a   Rajkumar, S V ^b   Dimopoulos, M A ^c   Richardson, P G ^d   San Miguel, J ^e   Barlogie, B ^f   Harousseau, J ^g   Zonder, J A ^h   Cavo, M ⁱ   Zangari, M ^f   Attal, M ^j   Belch, A ^k   Knop, S ^l   Joshua, D ^m   Sezer, O ^ad   Ludwig, H ⁿ   Vesole, D ^o   Blade J ^p   Kyle, R ^q   Westin, J ^r   Weber, D ^s   Bringhen, S ^a   Niesvizky, R ^t   Waage, A ^u   von Lilienfeld Toal, M ^v   Lonial, S ^w   Morgan, G J ^x   Orlowski, R Z ^y   Shimizu, K ^z   Anderson, K C ^d   Boccadoro, M ^a   Durie, B G ^aa   Sonneveld, P ^ab   Hussein, M A ^ac   more..

^a UNIVERSITY OF TURIN   (Italy)

^b Mayo Clinic   (United States)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^f UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^g HÔTEL DIEU   (France)

^h WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF BOLOGNA   (Italy)

^j CHU PURPAN   (France)

^k CROSS CANCER INSTITUTE   (Canada)

^l UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^m ROYAL PRINCE ALFRED HOSPITAL   (Australia)

ⁿ WILHELMINEN HOSPITAL   (Austria)

^o ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

^p UNIVERSITY OF BARCELONA   (Spain)

^q MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^r LUND UNIVERSITY   (Sweden)

^s UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^t WEILL CORNELL MEDICAL COLLEGE   (United States)

^u TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^v ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^w EMORY UNIVERSITY   (United States)

^x ROYAL MARSDEN HOSPITAL   (United Kingdom)

^y UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^z Nagoya City Midori General Hospital   (Japan)

^aa CEDARS SINAI MEDICAL CENTER   (United States)

^ab ERASMUS MEDICAL CENTER   (Netherlands)

^ac TAUSSIG CANCER INSTITUTE   (United States)

^ad CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DALTEPARIN; DEXAMETHASONE; DOXORUBICIN; ENOXAPARIN; ERYTHROPOIETIN; ETOPOSIDE; FONDAPARINUX; HEPARIN; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; NADROPARIN; PLACEBO; PREDNISONE; THALIDOMIDE; VINCRISTINE; WARFARIN;

AGE; ARTICLE; BLEEDING; BLOOD VISCOSITY; CANCER PATIENT; CENTRAL VENOUS CATHETER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG MEGADOSE; ECHOGRAPHY; EVIDENCE BASED MEDICINE; HEART DISEASE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMMOBILIZATION; INCIDENCE; INFECTION; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; LUNG ANGIOGRAPHY; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MONOTHERAPY; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIMAL DRUG DOSE; PATIENT MONITORING; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SURGICAL TECHNIQUE; THROMBOPHILIA; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

EID: 39149109289     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2405062     Document Type: Article

References (99)

1. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism. A 25-year population-based study. Arch Intern Med 1998; 158: 585-593.
2. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: Determination of frequency and characteristics. Thromb Haemost 2002; 87: 575-579.
3. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancy, prathrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293 715-722.
4. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton III LJ. Predictors of survival after deep vein thrombosis and pulmonary embolism: A population-based cohort study. Arch Intern Med 1999; 159: 445-453.
5. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: The Sirius study. Arch Intern Med 2000; 160: 3415-3420.
6. Heit JA, Silverstein MID, Mohr DN, Petterson TM, O'Fallon WM, Melton III LJ. Risk factors for deep vein thrombosis and pulmonary embolism. Arch Intern Med 2000; 160: 809-815.
7. Heit JA, O'Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism. Arch Intern Med 2002; 162: 1245-1248.
8. Ageno W, Squizzato A, Garcia D, Imberti D. Epidemiology and risk factors of venous thromboembolism. Semin Thromb Hemost 2006; 32 651-658.
9. Bauer KA. The thrombophilias: Well-defined risk factors with uncertain therapeutic implications. Ann Intern Med 2001; 135: 367-373.
10. Bick RL. Cancer-associated thrombosis. N Engl J Med 2003; 349 109-111.
11. Prandoni P, Falanga A, Piccioli A. Cancer and venous thrombo-embolism. Lancet Oncol 2005; 6: 401-410.
12. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with mode-negative breast cancer who have estrogenreceptor-positive tumors. N Engl J Med 1989; 320: 479-484.
13. Fisher B, Dignam J, Wolmark N, DeCillis A. Emir B, Wickerham DL et al Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor positive breast cancer. J Natl Cancer Inst 1997; 89 1673-1682.
14. White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 2003; 90: 446-455.
15. Bona RD. Thrombotic complications of central venous catheters in cancer patients. Semin Thromb Haemost 1999; 25: 147-155.
16. Bern MM, Lokich JJ, Wallach SR, Bothe Jr A, Benotti PN, Arkin CF et al. Very. low doses of warfarin can prevent thrombosis in central venous catheters: A randomized prospective trial. Ann Intern Med 1990; 112: 423-428.
17. Monreal,M, Alastrue A. Rull M, Mira X, Muxart J, Rosell R et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices-prophylaxis with low molecular weight heparin (Fragmin). Thromb Haemost 1996; 75: 251-253.
18. Verso M, Agnelli G. Venous thromboembolism associated with long term use of central venous catheters in cancer patients. J Clin Oncol 2003; 21: 3665-3675.
19. FDA Alert. Information For Healthcare Professional: Eyrthropoiesis Stimulating Agents (ESA) [Aranesp (Darbopoietin), Epogen (Epoietin Alfa), and Procrit (Epoietin Alfa)]. Food and Drug Administration: Rockville, MD, March 9, 2007. Accessed May 25, 2007, at http://www.fda.gov/cder/drug/InfoSheets/HCP/RHE2007HCP.htm.
20. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M et al. Correction of anemia with epoietin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098.
21. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084.
22. Sallah S, Husain A, Wan J, Vos P, Nguyen NP. The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. Ann Oncol 2004; 15: 1490-1494.
23. Srkalovic G, Cameron MG, Rybicki L, Deitcher SR, Kattke-Marchant K, Hussein MA. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 2004; 101: 558-566.
24. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR, Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431-436.
25. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 2006; 367 825-831.
26. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B et al Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): A randomized trial. Lancet 2007; 370: 1209-1218.
27. Zangari M, Saghafifar F, Mehta P, Barlogie B, Fink L, Tricot G. The blood coagulation mechanism in multiple myeloma. Semin Thromb Hemost 2003; 29: 275-282.
28. Fox EA, Kahn SR. The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. Thromb Haemost 2005; 94: 362-365.
29. Auwerda JJA, Sonneveld P, de Maat MPM, Leebeek FWG. Prothromboic coagulation abnormalities in patients with newly diagnosed multiple myeloma. Haematologica 2007; 92: 279-280.
30. Rajkumar SV, Gertz MA, Lacy MQ Dispenzieri A, Fonseca R, Geyer SM et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003; 17: 775-779.
31. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16-19.
32. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of T69 patients. Blood 2001; 98: 492-494.
33. Neben K, Moehler T, Benner A, Kraemer A, Egerer G, Ho, AD et al. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin. Cancer Res 2002; 8: 3377-3382.
34. Schey SA, Cavenagh J, Johnson R, Child JA, Oakervee H, Jones RW. An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment. Leuk Res 2003; 27: 909-914.
35. Cavo M, Zamagni E, Tosi P, Cellini C, Cangini D, Tacchetti P et al First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004; 89: 826-831.
36. Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002: 20: 4319-4323.
37. Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 2003; 121: 768-771.
38. Palumbo A, Bertola A, Falco P, Rosato R, Cavallo F, Giaccone L et al Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J 2004; 5: 318-324.
39. Dimopoulos MA, Anagnostopoulos A, Terpos E, Repoussis P, Zomas A, Katodritou E et al. Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. Haematologica 2006; 91: 252-254.
40. Offidani M, Corvatta L, Marconi M, Olivieri A, Catarini M, Mele A et al. Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma. Hematol 2004; 5: 312-317.
41. Osman K, Comenzo R, Rajkumar SV. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 2001; 344: 1951.
42. Schutt P, Ebeling P, Buttkereit U, Brandhorst D, Opalka B, Poser M et al. Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma. Eur J Haematol 2005; 74: 40-46.
43. Zervas K, Dimopoulos MA, Hatzicharissi E, Anagnostopoulos A, Papaioannou M, Mitsouli Ch et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): A phase II multicenter study. Ann Oncol 2004; 15: 134-138.
44. Baz R, Li L, Kottke-Marchant K, Srkalovic G, McGowan B, Yiannaki E et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 2005; 80: 1568-1574.
45. Sidra G, Williams CD, Russell NH, Zaman S, Myers B, Byrne JL. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma. Haematologica 2006; 91: 862-863.
46. Wu P, Davies FE, Horton C, Jenner MW, Krishnan B, Alvares CL et al The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide- vincristine-doxorubicin-methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: A case-matched analysis. Leuk Lymphoma 2006; 47: 2335-2338.
47. Dimopoulos MA, Hamilos G, Zomas A, Gika D, Efstathiou E, Grigoraki V et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: An oral regimen for previously treated patients with multiple myeloma. Hematol J 2004; 5: 112-117.
48. Garcia-Sanz R, Gonzalez-Porras JR, Hernandez JM, Polo-Zarzuela M, Sureda A, Barrenetxea C et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/ refractory multiple myeloma. Leukemia 2004; 18: 856-863.
49. Kropff MH, Lang N, Bisping G, Dominé N, Innig G, Hentrich M et al Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol 2003; 122: 607-616.
50. Suvannasankha A, Fausel C, Juliar BE, Yiannoutsos CT, Fisher WB, Ansari RH et al. Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21. Oncologist 2007; 12: 99-106.
51. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021-1030.
52. Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: Implications for therapy. Blood 2002; 100: 1168-1171.
53. Lee C-K, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J et al DTPACE: An effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003; 21: 2732-2739.
54. Zonder JA. Thrombotic complications of myeloma therapy. Hematology Am Soc Hematol Educ Program 2006; 1: 348-355.
55. Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063-3067.
56. Zangari M, Tricot G, Zeldis J, Eddlemon P, Saghafifar F, Barlogie B. Results of phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy. Blood 2001; 98: 775a (abstract [3226]).
57. Zonder JA, Barlogie B, Durie BG, McCoy J, Crowley J, Hussein MA. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone benefit of aspirin prophylaxis. Blood 2006; 108: 403.
58. Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Williams M et al. Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2007; 25: 447s (abstract [8025]).
59. Dimopoulos MA, Spencer A, Attal M, Prince M, Harousseau J, Dmoszynska A et al. Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a phase 3 study (MM-010). Blood 2005; 106: 6a (abstract [6]).
60. Weber D, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer E et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of a North American phase III study (MM-009). J Clin Oncol 2006; 24: 427s (abstract [7521]).
61. Morgan GJ, Schey SA, Wu P, Srikanth M, Phekoo KJ, Jenner M et al. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol 2007; 137: 268-269.
62. Richardson P, Schlossman R, Munshi N, Avigan D, Jagannath S, Alsina M et al. A phase 1 trial of lenalidomide (REVLIMID(R)) with bortezomib (VELCADE(R)) in relapsed and refractory multiple myeloma. Blood 2005; 106: 110a (abstract [365]).
63. Zangari M, Barlogie B, Thertulien R, Jacobson J, Eddleman P, Fink L et al. Thalidomide and deep vein thrombosis in multiple myeloma: Risk factors and effect on survival. Clin Lymphoma 2003; 4: 32-35.
64. Galli M, Elice F, Crippa C, Comotti B, Rodeghiero F, Barbui T. Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma. Haematologica 2004; 89: 1141-1142.
65. Knight R, DeLap RJ, Zeldis JB. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 2006; 354: 2079-2080.
66. Cohen AT, Alikhan R, Arcelus JI, Bergmann JF, Haas S, Merli GJ et al Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost 2005; 94 750-759.
67. Haas SK. Venous thromboembolic risk and its prevention in hospitalized medical patients. Semin Thromb Hemost 2002; 28: 577-584.
68. Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA. Meta-anlaysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 2007; 146: 278-288.
69. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C et al A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999; 341: 793-800.
70. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ, PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 874-879.
71. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: Randomized placebo controlled trial. BMJ 2006; 332: 325-329.
72. Mismetti P, Laporte-Simitsidis S, Tardy B, Cucherat M, Buchmuller A, Juillard-Delsart D et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomized clinical trials. Thromb Haemost 2000; 83: 14-19.
73. Francis CW. Prophylaxis for thromboembolism in hospitalized medical patients. N Engl J Med 2007; 356: 1438-1444.
74. Geerts WH, Pineo GF, Heit JA, Berggvist D, Lassen MR, Colwell CW et al. Prevention of venous thromboembolism: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 338-400.
75. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: III. reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 1994; 308: 235-246.
76. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000; 355: 1295-1302.
77. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A et al Prevention of venous thromboembolism in medical patients with enoxaparin: A subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis 2003; 12: 341-346.
78. Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A et al. Double-bind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343 886-889.
79. Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2CS polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000; 96: 1816-1819.
80. Wang M, Weber D, Delasalle K, Alexanian R. Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma. Am J Hematol 2005; 79: 194-197.
81. Minnema MC, Breitkreutz I, Auwerda JJ, van der Holt B, Cremer FW, van Marion AM et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 2004; 18: 2044-2046.
82. Offidani M, Corvetta L, Piersantelli MN, Visani G, Alesiani F, Brunori M et al. Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood 2006; 108: 2159-2164.
83. Zangari M, Barlogie B, Anaissie E, Saghafifar F, Eddlemon P, Jacobson J et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: Effects of prophylactic and therapeutic anticoagulatiQn. Br J Haematol 2004; 126: 715-721.
84. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B et al. Combination therapy with lenalidomide plus dexamethasone (Rev/ Dex) for newly diagnosed myeloma. Blood 2005; 106: 4050-4053.
85. Palumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F, Giuliani N et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma. J Clin Oncol 2007; 25: 4459-4465.
86. Baz R, Walker E, Karam MA, Choueiri TK, Jawde RA, Bruening K et al Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myelomo: Safety and efficacy. Ann Oncol 2006; 17: 1766-1771.
87. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention for atherothrombosis. N Engl J Med 2005; 353 2373-2383.
88. US Food and Drug Administration Web site. Thalidomide package insert. http:/Www.fda.gav/cder/foi/label/2006/021430s000,020785s031lbl.pdf. Accessed September 6 2006.
89. US Food and Drug Administration Web site. Lenalidomide package insert http:/Www.fda.gov/cder/foi/label/2006(021880s001.pdf. Accessed September 6 2006.
90. Zangari M, Barlogie B, Lee CK, Tricot AE, Fassas A, Anaissie E et al Protective effect of VELCADE® on thalidomide-associated deep vein thrombosis (DVT). Blood 2004; 104: 13a (abstract [4914]).
91. Cestac P, Bagheri H, Lapeyre-Mestre M, Sie P, Fouladi A, Maupas E et al. Utilisition and safety of low molecular weight heparins: prospective observational study in medical inpatients. Drug Saf 2003; 26: 197-207.
92. Nagge J, Crowther M, Hirsh J. Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med 2002; 162: 2605-2609.
93. Thromboembolic Risk Factors (THRIFT) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. BMJ 1992; 305: 567-574.
94. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: The Seventh ACCP Conference on Antithrombotic and Thromholytic Therapy. Chest 2004; 126 (Suppl 3): 483S-512S.
95. Lagerstedt CI, Olsson CB, Fagher BO, Oqvist BW, Albrechtsson U. Need for long term anticoagulant treatment in patients with symptomatic calf-vein thrombosis. Lancet 1985; 2: 515-518.
96. Moser KM, Fedullo PF, Littlejohn JK, Crawford R. Frequent asymptomatic pulmonary embolism in patients with deep venous thrombosis. JAMA 1994; 271: 223-225.
97. Bozlar U, Gaughen JR, Nambiar AP, Hagspiel KD. Imaging diagnosis of acute pulmonary embolism. Expert Rev Cardiovasc Ther 2007; 5 519-529.
98. Baglin T, Luddington R, Brown K, Baglin C. incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362: 523-526.
99. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Martin Prins MB et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153.